Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.